She was treated with liraglutide monotherapy, starting with 0.6 mg subcutaneously once daily then titrating weekly to 1.8 mg subcutaneously
Retatrutide Retatrutide is a triple agonist (GIP/GLP-1/glucagon receptor) currently in late-stage clinical trials that has shown remarkable weight loss results of up to 24% in Phase 2 studies
The 47-year-old, from King's Lynn in Norfolk, inhaled the spray twice a day, believing it would give her tan "time to build up before we actually get into the sunshine"
If you have sleep apnea and want GLP-1 coverage through the OSA indication, ask your doctor about Zepbound instead
Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J